Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064.

Author information

Affiliations

  • 1. Cancer Research Unit, University of Newcastle upon Tyne, Medical School, UK.
      Authors
    • Bowman KJ 1
    (1 author)

ORCIDs linked to this article

British Journal of Cancer, 01 Nov 1998, 78(10):1269-1277
https://doi.org/10.1038/bjc.1998.670 PMID: 9823965 PMCID: PMC2063197

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

Abstract 

The ability of the potent poly(ADP-ribose) polymerase (PARP) inhibitor, NU1025 (8-hydroxy-2-methyl-quinazolin-4-[3H]one) to potentiate the cytotoxicity of a panel of mechanistically diverse anti-cancer agents was evaluated in L1210 cells. NU1025 enhanced the cytotoxicity of the DNA-methylating agent MTIC, gamma-irradiation and bleomycin 3.5-, 1.4- and 2-fold respectively. The cytotoxicities of the thymidylate synthase inhibitor, nolatrexed, and the cytotoxic nucleoside, gemcitabine, were not increased. Potentiation of MTIC cytotoxicity by a delayed exposure to NU1025 was equally effective as by a simultaneous exposure to NU1025, indicating that the effects of NU1025 were mediated by an inhibition of the cellular recovery. The recovery from potentially lethal gamma-irradiation damage cytotoxicity in plateau-phase cells was also inhibited by NU1025. Investigation of DNA strand breakage and repair in gamma-irradiated cells by alkaline elution demonstrated that NU1025 caused a marked retardation of DNA repair. A structurally different PARP inhibitor, NU1064 (2-methylbenzimidazole-4-carboxamide), also potentiated the cytotoxicity of MTIC, to a similar extent to NU1025. NU1064 potentiated a sublethal concentration of a DNA methylating agent in a concentration-dependent manner. Collectively, these data suggest that the most suitable cytotoxic agents for use in combination with PARP inhibitors are methylating agents, bleomycin and ionizing radiation, but not anti-metabolites.

Free full text 

Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 1998 Nov; 78(10): 1269–1277.
PMCID: PMC2063197
PMID: 9823965

Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064.

K. J. Bowman, A. White, B. T. Golding, R. J. Griffin, and N. J. Curtin
Author information Copyright and License information Disclaimer

Abstract

The ability of the potent poly(ADP-ribose) polymerase (PARP) inhibitor, NU1025 (8-hydroxy-2-methyl-quinazolin-4-[3H]one) to potentiate the cytotoxicity of a panel of mechanistically diverse anti-cancer agents was evaluated in L1210 cells. NU1025 enhanced the cytotoxicity of the DNA-methylating agent MTIC, gamma-irradiation and bleomycin 3.5-, 1.4- and 2-fold respectively. The cytotoxicities of the thymidylate synthase inhibitor, nolatrexed, and the cytotoxic nucleoside, gemcitabine, were not increased. Potentiation of MTIC cytotoxicity by a delayed exposure to NU1025 was equally effective as by a simultaneous exposure to NU1025, indicating that the effects of NU1025 were mediated by an inhibition of the cellular recovery. The recovery from potentially lethal gamma-irradiation damage cytotoxicity in plateau-phase cells was also inhibited by NU1025. Investigation of DNA strand breakage and repair in gamma-irradiated cells by alkaline elution demonstrated that NU1025 caused a marked retardation of DNA repair. A structurally different PARP inhibitor, NU1064 (2-methylbenzimidazole-4-carboxamide), also potentiated the cytotoxicity of MTIC, to a similar extent to NU1025. NU1064 potentiated a sublethal concentration of a DNA methylating agent in a concentration-dependent manner. Collectively, these data suggest that the most suitable cytotoxic agents for use in combination with PARP inhibitors are methylating agents, bleomycin and ionizing radiation, but not anti-metabolites.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.4M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
 
icon of scanned page 1269
1269
icon of scanned page 1270
1270
icon of scanned page 1271
1271
icon of scanned page 1272
1272
icon of scanned page 1273
1273
icon of scanned page 1274
1274
icon of scanned page 1275
1275
icon of scanned page 1276
1276
icon of scanned page 1277
1277
 

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Althaus FR, Höfferer L, Kleczkowska HE, Malanga M, Naegeli H, Panzeter P, Realini C. Histone shuttle driven by the automodification cycle of poly(ADP-ribose)polymerase. Environ Mol Mutagen. 1993;22(4):278–282. [Abstract] [Google Scholar]
  • Arundel-Suto CM, Scavone SV, Turner WR, Suto MJ, Sebolt-Leopold JS. Effect of PD 128763, a new potent inhibitor of poly(ADP-ribose) polymerase, on X-ray-induced cellular recovery processes in Chinese hamster V79 cells. Radiat Res. 1991 Jun;126(3):367–371. [Abstract] [Google Scholar]
  • Ben-Hur E, Chen CC, Elkind MM. Inhibitors of poly(adenosine diphosphoribose) synthetase, examination of metabolic perturbations, and enhancement of radiation response in Chinese hamster cells. Cancer Res. 1985 May;45(5):2123–2127. [Abstract] [Google Scholar]
  • Boulikas T. Relation between carcinogenesis, chromatin structure and poly(ADP-ribosylation) (review). Anticancer Res. 1991 Mar-Apr;11(2):489–527. [Abstract] [Google Scholar]
  • Boulton S, Pemberton LC, Porteous JK, Curtin NJ, Griffin RJ, Golding BT, Durkacz BW. Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. Br J Cancer. 1995 Oct;72(4):849–856. [Europe PMC free article] [Abstract] [Google Scholar]
  • Chen TR. In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. Exp Cell Res. 1977 Feb;104(2):255–262. [Abstract] [Google Scholar]
  • Cleaver JE, Morgan WF. Poly(ADP-ribose)polymerase: a perplexing participant in cellular responses to DNA breakage. Mutat Res. 1991 Jan;257(1):1–18. [Abstract] [Google Scholar]
  • Huang P, Plunkett W. Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol. 1995;36(3):181–188. [Abstract] [Google Scholar]
  • Huet J, Laval F. Potentiation of cell killing by inhibitors of poly(adenosine diphosphate-ribose) synthesis in bleomycin-treated Chinese hamster ovary cells. Cancer Res. 1985 Mar;45(3):987–991. [Abstract] [Google Scholar]
  • Hunting DJ, Gowans BJ, Henderson JF. Specificity of inhibitors of poly(ADP-ribose) synthesis. Effects on nucleotide metabolism in cultured cells. Mol Pharmacol. 1985 Aug;28(2):200–206. [Abstract] [Google Scholar]
  • Kato T, Suzumura Y, Fukushima M. Enhancement of bleomycin activity by 3-aminobenzamide, a poly (ADP-ribose) synthesis inhibitor, in vitro and in vivo. Anticancer Res. 1988 Mar-Apr;8(2):239–243. [Abstract] [Google Scholar]
  • Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res. 1993 Sep 1;53(17):3976–3985. [Abstract] [Google Scholar]
  • Küpper JH, van Gool L, Bürkle A. Molecular genetic systems to study the role of poly(ADP-ribosyl)ation in the cellular response to DNA damage. Biochimie. 1995;77(6):450–455. [Abstract] [Google Scholar]
  • Lautier D, Lagueux J, Thibodeau J, Ménard L, Poirier GG. Molecular and biochemical features of poly (ADP-ribose) metabolism. Mol Cell Biochem. 1993 May 26;122(2):171–193. [Abstract] [Google Scholar]
  • Lindahl T, Satoh MS, Poirier GG, Klungland A. Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks. Trends Biochem Sci. 1995 Oct;20(10):405–411. [Abstract] [Google Scholar]
  • Milam KM, Thomas GH, Cleaver JE. Disturbances in DNA precursor metabolism associated with exposure to an inhibitor of poly(ADP-ribose) synthetase. Exp Cell Res. 1986 Jul;165(1):260–268. [Abstract] [Google Scholar]
  • Molinete M, Vermeulen W, Bürkle A, Ménissier-de Murcia J, Küpper JH, Hoeijmakers JH, de Murcia G. Overproduction of the poly(ADP-ribose) polymerase DNA-binding domain blocks alkylation-induced DNA repair synthesis in mammalian cells. EMBO J. 1993 May;12(5):2109–2117. [Europe PMC free article] [Abstract] [Google Scholar]
  • Moses K, Harris AL, Durkacz BW. Adenosine-diphosphoribosyltransferase inhibitors can protect against or potentiate the cytotoxicity of S-phase acting drugs. Biochem Pharmacol. 1988 Jun 1;37(11):2155–2160. [Abstract] [Google Scholar]
  • de Murcia G, Ménissier de Murcia J. Poly(ADP-ribose) polymerase: a molecular nick-sensor. Trends Biochem Sci. 1994 Apr;19(4):172–176. [Abstract] [Google Scholar]
  • Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev. 1997 Jan;23(1):35–61. [Abstract] [Google Scholar]
  • Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995 Aug;22(4 Suppl 11):3–10. [Abstract] [Google Scholar]
  • Prise KM, Gaal JC, Pearson CK. Increased protein ADPribosylation in HeLa cells exposed to the anti-cancer drug methotrexate. Biochim Biophys Acta. 1986 Jun 16;887(1):13–22. [Abstract] [Google Scholar]
  • Satoh MS, Lindahl T. Role of poly(ADP-ribose) formation in DNA repair. Nature. 1992 Mar 26;356(6367):356–358. [Abstract] [Google Scholar]
  • Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, Baig G, Goddard C, Gibson NW, Slack JA, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res. 1987 Nov 15;47(22):5846–5852. [Abstract] [Google Scholar]
  • Webber S, Bartlett CA, Boritzki TJ, Hillard JA, Howland EF, Johnston AL, Kosa M, Margosiak SA, Morse CA, Shetty BV. AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies. Cancer Chemother Pharmacol. 1996;37(6):509–517. [Abstract] [Google Scholar]
  • Wang ZQ, Auer B, Stingl L, Berghammer H, Haidacher D, Schweiger M, Wagner EF. Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease. Genes Dev. 1995 Mar 1;9(5):509–520. [Abstract] [Google Scholar]
  • Willmore E, Durkacz BW. Cytotoxic mechanisms of 5-fluoropyrimidines. Relationships with poly(ADP-ribose) polymerase activity, DNA strand breakage and incorporation into nucleic acids. Biochem Pharmacol. 1993 Jul 20;46(2):205–211. [Abstract] [Google Scholar]
Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

Full text links 

Read article at publisher's site: https://doi.org/10.1038/bjc.1998.670

Read article for free, from open access legal sources, via Unpaywall: https://europepmc.org/articles/pmc2063197?pdf=renderUnpaywall

Citations & impact 

Impact metrics

71
Citations
Jump to Citations
1
Data citation
Jump to Data

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/23984062
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/23984062

Article citations

Go to all (71) article citations

Data 

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.